Pfizer's blockbuster smoking cessation drug Chantix ushered in imitation products threatened

CompilationFan Dongdong

Recently, Pfizer's smoking cessation drug Chantix's dominance in the field of smoking treatment seems to be threatened

Although Pfizer Chantix's competitor, Par Pharmaceuticals, received accelerated approval from the FDA, it is not surprising that Chantix lost its main patent protection in November last year

According to the pharmaceutical e-commerce company GoodRx, Pfizer Chantix’s sales growth is largely attributable to the company’s multiple price increases for the drug over the years

Chantix is ​​a partial agonist of nicotine receptors, which can combine with nicotine receptors to exert a smoking cessation mechanism

In July of this year, Pfizer has voluntarily recalled 12 batches of the smoking cessation drug Chantix.

For months, people trying to quit smoking have been facing a shortage of Chantix after Pfizer stopped its global distribution of Chantix at the end of June

In recent years, it is not uncommon for foreign pharmaceutical manufacturers to recall drugs due to carcinogenic impurities

Reference source: Pfizer halted Chantix distribution then recalled a dozen batches.